Inovio Pharmaceuticals (MEX:INO) Gross Property, Plant and Equipment: MXN150.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INO Inovio Pharmaceuticals Inc MEX:INO
40 GF Score
Price MXN11.50
GF Value MXN3.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Gross Property, Plant and Equipment?

Inovio Pharmaceuticals MEX:INO -36.11% 40 Gross Property, Plant and Equipment is MXN150.12 Mil as of Mar. 2026. GuruFocus rates MEX:INO with a GF Score™ of 40/100 and a GF Value™ of MXN3.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Inovio Pharmaceuticals's quarterly gross PPE increased from Sep. 2025 (MXN177.88 Mil) to Dec. 2025 (MXN477.01 Mil) but then declined from Dec. 2025 (MXN477.01 Mil) to Mar. 2026 (MXN150.12 Mil).

Inovio Pharmaceuticals's annual gross PPE stayed the same from Dec. 2023 (MXN599.28 Mil) to Dec. 2024 (MXN588.88 Mil) but then declined from Dec. 2024 (MXN588.88 Mil) to Dec. 2025 (MXN477.01 Mil).


Inovio Pharmaceuticals  (MEX:INO) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Inovio Pharmaceuticals Gross Property, Plant and Equipment Related Terms


Inovio Pharmaceuticals Gross Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Gross Property, Plant and Equipment Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 984.04 770.48 599.28 588.88 477.01

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.88 196.69 177.88 477.01 150.12
MEX:INO
40GF Score
Inovio Pharmaceuticals Inc MEX:INO
Gross Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Gross Property, Plant and Equipment of MXN150.12 Mil mean?
Inovio Pharmaceuticals (MEX:INO) has a Gross Property, Plant and Equipment of MXN150.12 Mil as of Mar. 2026. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Gross Property, Plant and Equipment too high?
Inovio Pharmaceuticals' current Gross Property, Plant and Equipment is MXN150.12 Mil. Overall, Inovio Pharmaceuticals has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Gross Property, Plant and Equipment compare to TELO and ELTX?
Inovio Pharmaceuticals' Gross Property, Plant and Equipment of MXN150.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Property, Plant and Equipment for a Biotechnology company?
A good Gross Property, Plant and Equipment depends on the Biotechnology industry context. However, Gross Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Property, Plant and Equipment mean?
A high Gross Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total gross property, plant and equipment assets recorded on a company's balance sheet. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Gross Property, Plant and Equipment is MXN150.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (MEX:INO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3.68, compared to a current price of MXN11.50 — trading 212.5% above its estimated fair value. The current Gross Property, Plant and Equipment is MXN150.12 Mil. Inovio Pharmaceuticals' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Property, Plant and Equipment calculated?
Gross Property, Plant and Equipment is calculated from a company's financial statements. For Inovio Pharmaceuticals (MEX:INO), the current Gross Property, Plant and Equipment is MXN150.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of MXN11.50 is trading 212.5% above its estimated GF Value™ of MXN3.68. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:INO:

  • Gross Property, Plant and Equipment: MXN150.12 Mil
  • GF Value™: MXN3.68 vs. price of MXN11.50 (212.5% above fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Other Exchanges INO:USA0A43:UKGBM:Germany
Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
40GF Score

Get the complete analysis for MEX:INO

Gross Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN11.50
Price
MXN3.68
GF Value